Physician

Robert Edward Reynolds, MD

According to 2025 Medicare claims, Robert Reynolds, MD (NPI: 1649275827) practices medical oncology in the Oklahoma City, OK market, with the plurality of this provider's patient population coming from Oklahoma, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER AND BLOOD SPECIALISTS, LLC (NPI: 1831485267; TIN: 20-2001573) and primary practice location at 73120-5049. Reynolds is affiliated with the Mercy Health ACO, LLC (ACO ID: A2616), participating under the MSSP model.

Reynolds' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 506 traditional Medicare patients, billed 241,320 HCPCS/CPT codes, and received $5,621,070 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,224 prescription claims across 278 beneficiaries totaling $5,122,218 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 16 claims. Open Payments data shows 145 records totaling $3,032. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,925,121 to $5,621,070. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $955,108 to $5,122,218. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $20,139 to $3,936.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	569	119,514	$1,925,121
2016	630	126,435	$2,125,052
2017	546	127,572	$2,110,686
2018	647	189,993	$3,726,964
2019	646	192,702	$3,906,636
2020	496	163,278	$3,422,161
2021	489	151,363	$3,480,666
2022	464	137,628	$3,474,766
2023	409	160,710	$4,250,045
2024	506	241,320	$5,621,070

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	209	1,833	$955,108
2016	210	1,718	$1,405,449
2017	220	1,967	$1,759,333
2018	243	2,106	$1,428,930
2019	260	2,389	$2,701,707
2020	247	2,451	$3,308,816
2021	255	2,306	$3,801,213
2022	253	2,215	$4,146,919
2023	255	2,073	$4,086,322
2024	278	2,224	$5,122,218

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	32	205	$19,375
2016	26	139	$22,055
2017	N/R	60	$2,479
2018	N/R	30	$1,785
2019	N/R	44	$1,807
2020	N/R	75	$4,667
2021	N/R	71	$4,635
2022	N/R	37	$1,638
2023	N/R	15	$263
2024	N/R	16	$1,417

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	119	119	$153
96413	Administration of chemotherapy into vein, 1 hour or less	90	715	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	119	159	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	461	1,666	$65
96372	Injection of drug or substance under skin or into muscle	77	499	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	37	1,110	$662,162
Bosulif	Bosutinib	34	1,020	$556,125
Xtandi	Enzalutamide	37	1,110	$525,890
Imbruvica	Ibrutinib	26	728	$426,078
Lenalidomide	Lenalidomide	23	644	$289,303

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	16	$1,417

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	145	$3,032	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert Edward Reynolds, MD?

Tedicare shows public-source Medicare data for Robert Edward Reynolds, MD (NPI 1649275827), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert Edward Reynolds, MD have ACO affiliation data?

Robert Edward Reynolds, MD is shown with ACO affiliation data for Mercy Health ACO, LLC (MSSP, ACO ID A2616).

What billing organization is linked to Robert Edward Reynolds, MD?

Robert Edward Reynolds, MD is linked to OKLAHOMA CANCER AND BLOOD SPECIALISTS, LLC (billing NPI 1831485267) in the available physician profile data.

Does Robert Edward Reynolds, MD have Open Payments data?

Robert Edward Reynolds, MD has 145 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.